Near-infrared photoimmunotherapy for salivary duct carcinoma
Copyright © 2023. Published by Elsevier B.V..
In Japan, near-infrared photoimmunotherapy (NIR-PIT) was introduced in 2021 as a treatment option for unresectable recurrent head and neck cancer. The treatment targets the epidermal growth factor receptor (EGFR), which is overexpressed in 80-90 % of head and neck squamous cell carcinoma (HNSCC). NIR-PIT should theoretically show therapeutic efficacy if EGFR is expressed, even in nonsquamous cell carcinomas (non-SCC). To the best of our knowledge, there are no case reports of NIR-PIT for non-SCC. We performed NIR-PIT in a patient with non-SCC of the head and neck region. After performing two NIR-PIT treatments, small free clusters of residual tumor cells were observed. Immunostaining in this specimen revealed EGFR expression in residual tumor cells. The residual tumor cells had been irradiated sufficiently to achieve necrosis. It is suggested that not only laser irradiation and expression of EGFR but also other factors are involved in the efficacy of this treatment. Further investigation for these other factors is warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Auris, nasus, larynx - 51(2024), 2 vom: 18. Apr., Seite 323-327 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Makino, Takuma [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 01.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.anl.2023.09.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362715416 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362715416 | ||
| 003 | DE-627 | ||
| 005 | 20240401232349.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.anl.2023.09.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM362715416 | ||
| 035 | |a (NLM)37775468 | ||
| 035 | |a (PII)S0385-8146(23)00178-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Makino, Takuma |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Near-infrared photoimmunotherapy for salivary duct carcinoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a In Japan, near-infrared photoimmunotherapy (NIR-PIT) was introduced in 2021 as a treatment option for unresectable recurrent head and neck cancer. The treatment targets the epidermal growth factor receptor (EGFR), which is overexpressed in 80-90 % of head and neck squamous cell carcinoma (HNSCC). NIR-PIT should theoretically show therapeutic efficacy if EGFR is expressed, even in nonsquamous cell carcinomas (non-SCC). To the best of our knowledge, there are no case reports of NIR-PIT for non-SCC. We performed NIR-PIT in a patient with non-SCC of the head and neck region. After performing two NIR-PIT treatments, small free clusters of residual tumor cells were observed. Immunostaining in this specimen revealed EGFR expression in residual tumor cells. The residual tumor cells had been irradiated sufficiently to achieve necrosis. It is suggested that not only laser irradiation and expression of EGFR but also other factors are involved in the efficacy of this treatment. Further investigation for these other factors is warranted | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Epidermal growth factor receptor | |
| 650 | 4 | |a Head and neck cancer | |
| 650 | 4 | |a Nonsquamous cell carcinoma | |
| 650 | 4 | |a Photoimmunotherapy | |
| 650 | 4 | |a Salivary duct carcinoma | |
| 650 | 7 | |a Photosensitizing Agents |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Sato, Yasuharu |e verfasserin |4 aut | |
| 700 | 1 | |a Uraguchi, Kensuke |e verfasserin |4 aut | |
| 700 | 1 | |a Naoi, Yuto |e verfasserin |4 aut | |
| 700 | 1 | |a Fukuda, Yujiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ando, Mizuo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Auris, nasus, larynx |d 1993 |g 51(2024), 2 vom: 18. Apr., Seite 323-327 |w (DE-627)NLM000465496 |x 1879-1476 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2024 |g number:2 |g day:18 |g month:04 |g pages:323-327 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.anl.2023.09.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2024 |e 2 |b 18 |c 04 |h 323-327 | ||